Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Tania N. Masmas"'
Autor:
Sara Bohnstedt Mørup, Lusine Nazaryan-Petersen, Migle Gabrielaite, Joanne Reekie, Hanne V. Marquart, Hans Jakob Hartling, Rasmus L. Marvig, Terese L. Katzenstein, Tania N. Masmas, Jens Lundgren, Daniel D. Murray, Marie Helleberg, Line Borgwardt
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundKnowledge of the genetic variation underlying Primary Immune Deficiency (PID) is increasing. Reanalysis of genome-wide sequencing data from undiagnosed patients with suspected PID may improve the diagnostic rate.MethodsWe included patients
Externí odkaz:
https://doaj.org/article/2e05dd59a171477cb2f3ab6549040ea7
Autor:
Marianne Ifversen, Hanne Vibeke Marquart, Tania N. Masmas, Klaus Müller, Carsten Heilmann, Hans O. Madsen, Josefine Kofoed, Anna K. Haugaard
Publikováno v:
Blood Reviews. 44:100673
Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lowe
Autor:
Søren Lykke Petersen, Brian Kornblit, Henrik Sengeloev, Hans O. Madsen, Lars Vindeløv, Lone Schejbel, Peter Garred, Klaus Müller, Tania N. Masmas, Carsten Heilmann
Publikováno v:
Biology of Blood and Marrow Transplantation. 16:239-252
Abstract 2260 Poster Board II-237 Several studies have demonstrated that genetic variation in cytokine genes can modulate the immune reactions after allogeneic hematopoietic cell transplantation (HCT). High mobility group box 1 protein (HMBG1) is a p
Autor:
Sten Petersen, Lars P. Ryder, Gitte Olesen, Lars Vindeløv, Tania N. Masmas, Hans O. Madsen, Brian Kornblit, Ebbe Dickmeiss, Bodil K Jakobsen, Henrik Sengeløv, Carsten Heilmann, A. Svejgaard
Publikováno v:
Bone Marrow Transplantation. 41:851-859
We analysed the outcome and hospitalization requirements of the first 100 patients (Hodgkin's disease (HD), N=13; multiple myeloma (MM), N=14; CLL, N=12; non-Hodgkin's lymphoma (NHL), N=17; myelodysplastic syndrome (MDS), N=18; AML, N=24 and CML, N=2
Autor:
S Reker Hadrup, Mads Hald Andersen, Tania Køllgaard, Søren Lykke Petersen, P thor Straten, Hans O. Madsen, Lars Vindeløv, Tina Seremet, Tania N. Masmas
Publikováno v:
Leukemia. 19:2273-2280
We have analyzed the clonotype composition of CD8+ T cells following nonmyeloablative (NMA) conditioning and hematopoietic cell transplantation (HCT), of patients with chronic lymphocytic leukemia (CLL). Consecutive analyses of blood samples taken up
Autor:
Hans O. Madsen, Mehdi Alizadeh, Lars Vindeløv, Lars P. Ryder, Arne Svejgaard, Tania N. Masmas, Søren Lykke Petersen
Publikováno v:
Biology of Blood and Marrow Transplantation. 11:558-566
Chimerism analysis is an essential tool in the follow-up of patients after allogeneic stem cell transplantation. High-resolution methods for chimerism analysis based on real-time quantitative polymerase chain reaction (RQ-PCR) with a detection limit
Autor:
Hanne Vibeke Marquart, Lone Schejbel, Marianne Ifversen, Susanne Kjaergaard, Tania N. Masmas, Maria Kirchhoff, Carsten Heilmann, Jakob Ek, Klaus Müller
Publikováno v:
Journal of Clinical & Cellular Immunology.
Objective: Patients with primary immunodeficiencies (PID) verified by clinical disease and standard immunological diagnostics but without a genetic diagnosis remain a challenge. Genetic diagnosis is important in order to plan follow-up and treatment
Autor:
Brian Kornblit, Lars Vindeløv, Martin Thiim, Tania N. Masmas, Morten Nielsen, Ole Lund, Malene Erup Larsen, Peter Garred, Søren Buus, Mette Voldby Larsen, Anette Stryhn
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10)
In fully HLA-matched allogeneic hematopoietic cell transplantation (HCT), the main mechanism of the beneficial graft-versus-tumor (GVT) effect and of detrimental graft-versus-host disease (GVHD) is believed to be caused by donor cytotoxic T cells dir
Autor:
Mads Hald Andersen, Eric Spierings, T Kollgaard, S Reker Hadrup, Lars Vindeløv, P thor Straten, Tania N. Masmas, Søren Lykke Petersen
Publikováno v:
University of Copenhagen
Allogeneic hematopoietic cell transplantation (HCT) represents a potentially curative treatment modality for several hematologic malignancies. Conventional myeloablative conditioning regimens are associated with high treatment-related mortality. To t
Autor:
Lars P. Ryder, Lars Vindeløv, Pernille Andersen, Brian Kornblit, Hans O. Madsen, Ebbe Dickmeiss, Arne Svejgaard, Tania N. Masmas, Søren Lykke Petersen
Publikováno v:
American journal of hematology. 83(7)
Graft rejection after hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning is a rare but serious clinical problem. Graft rejection and salvage therapy in eight patients in a retrospective analysis of 124 consecutive patients is